- Home
- RLMD vs ZURA Comparison
RLMD vs ZURA Comparison
Compare RLMD & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RLMD | ZURA |
|---|---|---|
| Founded | 2004 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 307.3M | 252.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RLMD | ZURA |
|---|---|---|
| Price | $4.42 | $3.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $5.50 | ★ $11.38 |
| AVG Volume (30 Days) | ★ 1.1M | 398.3K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.24 | $0.97 |
| 52 Week High | $5.12 | $4.68 |
Technical Indicators
Market Signals| Indicator | RLMD | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 66.71 | 49.91 |
| Support Level | $3.95 | $3.66 |
| Resistance Level | $4.60 | $3.94 |
| Average True Range (ATR) | 0.43 | 0.23 |
| MACD | -0.07 | -0.03 |
| Stochastic Oscillator | 80.00 | 46.24 |
Price Performance
Historical ComparisonAbout RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.